Linping Hui

412 citations
13 papers · 299 indexed · h-index 9
Topics
RNA modifications and cancer (5 papers)Peptidase Inhibition and Analysis (2 papers)Ubiquitin and proteasome pathways (2 papers)
Journals
SHILAP Revista de lepidopterologíaPLoS ONEOncotarget
Partner nations
ChinaJapan

In The Last Decade

Linping Hui

13 papers receiving 292 citations

Peers

Linping Hui
Comparison fields: 5 of 63
  • Molecular Biology 211
  • Cancer Research 94
  • Oncology 85
  • Pulmonary and Respiratory Medicine 44
  • Immunology 37
Replace Hongjiu Ren with:
Hongjiu Ren China
Ana Rita Lourenço Netherlands
Shenyi Lian China
Sara S. Oltra Spain
Jidong Shan United States
Ryan H. Livengood United States
Yane Gao China
Guojun Lu China
Kyusam Choi South Korea
Linping Hui relative to Hongjiu Ren China Hongjiu Ren's profile →
Citations per field
00.5×6.5×
Hongjiu Ren · 1×
Citations per year

Countries citing papers authored by Linping Hui

Since Specialization
Citations

This map shows the geographic impact of Linping Hui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linping Hui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linping Hui more than expected).

Fields of papers citing papers by Linping Hui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linping Hui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linping Hui. The network helps show where Linping Hui may publish in the future.

Co-authorship network of co-authors of Linping Hui

This figure shows the co-authorship network connecting the top 25 collaborators of Linping Hui. A scholar is included among the top collaborators of Linping Hui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linping Hui. Linping Hui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
#WorkIndexed citations
1 33
2 23
3 23
4 24
5 28
6 5
7 33
8 86
9 3
10 23
11
Relationship between the Expression of PRDM14 in Non-small Cell Lung Cancer and the Clinicopathologic Characteristics
6
12 8
13 4

About Linping Hui

Linping Hui is a scholar working on Applied Microbiology and Biotechnology, Cancer Research and Molecular Biology, having authored 13 papers that have together received 299 indexed citations. Recurring topics across this work include RNA modifications and cancer (5 papers), Peptidase Inhibition and Analysis (2 papers) and Ubiquitin and proteasome pathways (2 papers). The work is most often cited by research in Cancer Research (94 citations), Oncology (85 citations) and Molecular Biology (211 citations). Linping Hui has collaborated with scholars based in China and Japan. Frequent co-authors include Xueshan Qiu, Siyang Zhang, Zeshi Cui, Da-Li Tian, Xin-Jun Dong, Hongjiu Ren, Yitong Xu, Jun Jiang, Chenyang Zhao and Enhua Wang. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026